Wednesday, March 12, 2025 The BLC4 (SWOG S1605): A Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer trial has permanently closed. This phase II trial studied how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Study results have been provided by the lead group to www.clinicaltrials.gov NCT02844816For more information please visit the BLC4 members trial page.
